Pfizer/BioNTech is currently seeking authorisation for a third dose of their Covid-19 vaccine to be used to increase its efficacy as the Delta variant continues to spread.
The Delta strain, which is understood to be the most infectious strain of the virus, was originally detected in India a few months ago but has since been the driving factor behind most new outbreaks throughout the world.
Tokyo has been placed under a virus state of emergency which will last throughout the entire Olympic events to which the majority of fans have been banned from.
The pharmaceutical company expects the third dose to be effective against the Delta variant and will be seeking authorisation for it to be used in the United States, Europe and other regions in the coming weeks.
A statement from the company stated that initial data from an ongoing trial revealed that a third dose of the vaccine pushed antibody levels five to ten times higher than the first two doses did against the original Covid-19 strain as well as the Beta variant.
Although similar results are expected for the Delta variant, a Delta-specific vaccine is also being developed by the company.
In relation to the need for booster shots, the Food and Drug Administration and the US Centres for Disease Control and Prevention stated, “Americans who have been fully vaccinated do not need a booster shot at this time,”.
The statement added, “We are prepared for booster doses if and when the science demonstrates that they are needed.”